NXY-059 Does Not Meet Efficacy Endpoints In Phase III Trial For Acute Ischemic Stroke

... Renovis, Inc. (Nasdaq: RNVS) announced today that a pivotal Phase III study of NXY-059 (SAINT II) conducted by its exclusive licensee, AstraZeneca, did not demonstrate a statistically significant reduction on the primary endpoint of stroke-related disability in patients treated with NXY-059, as assessed versus placebo using the modified Rankin Scale (mRS) (p=0.33, odds ratio 0.94). [click link for full article] ...